Biomerica, Inc. (BMRA) Stock Analysis
A live, multi-source view of Biomerica, Inc. (BMRA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Biomerica, Inc.
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria.
Sector: Healthcare · Industry: Medical Devices · United States · biomerica.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Biomerica, Inc. (BMRA) had a market capitalization of $10.6M (forward 5.9); the shares traded in a 52-week range of $1.45 – $3.21 (-23.7% over the year).
- Market cap
- $10.6M
- Enterprise value
- $11.7M
- Forward P/E
- 5.9
- Price / book
- 2.81
- EPS (trailing)
- $-1.34
- EPS (forward)
- $0.39
- Payout ratio
- 0.0%
- 52-week range
- $1.45 – $3.21
- 52-week change
- -23.7%
- Average volume
- 67,656
- Shares outstanding
- 4.6M
- Short % of float
- 0.64%
- Profit margin
- -84.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Biomerica, Inc. (BMRA) last closed at $2.27 (the last completed close before that scan).
Technicals at the scan: RSI 71 (overbought territory), price +20.7% versus its 20-day average, 20-day versus 50-day average spread +8.7%, MACD histogram 0.06.
Sentiment inputs: StockTwits 100% bullish.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of BMRA; corporate insiders filed 5 buys and 0 sells (5 distinct filers, latest disclosure 2026-08-27). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: David Moatazedi (1B/0S), Allen Barbieri (1B/0S), Zackary S. Irani (1B/0S), M. Huff Gary (1B/0S), Eric Chin (1B/0S). Who is trading what
RapidTradeView pick record
BMRA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Biomerica, Inc. (BMRA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell BMRA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.